Lista de obras - Michael Barnett - Dominio Público Uruguay

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application

scientific article published on 12 April 2016

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

artículo científico publicado en 2017

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

artículo científico publicado en 2017

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

artículo científico publicado en 2014

Comparative efficacy of switching to natalizumab in active multiple sclerosis

artículo científico publicado en 2015

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

scientific article published on 01 July 2020

Contribution of different relapse phenotypes to disability in multiple sclerosis.

artículo científico publicado en 2016

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

artículo científico publicado en 2012

Defining reliable disability outcomes in multiple sclerosis.

artículo científico publicado en 2015

Defining secondary progressive multiple sclerosis

artículo científico publicado en 2016

Diffusivity in multiple sclerosis lesions: At the cutting edge?

artículo científico publicado en 2016

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

artículo científico publicado en 2020

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

artículo científico publicado en 2016

Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients

scientific article published on 20 November 2020

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

artículo científico publicado en 2016

Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes)

artículo científico publicado en 2019

Incidence and prevalence of NMOSD in Australia and New Zealand.

artículo científico publicado en 2017

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

scientific article published on 03 January 2019

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

artículo científico publicado en 2015

Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.

artículo científico publicado en 2016

Molecular pathogenesis of neuromyelitis optica

artículo científico publicado en 2012

Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications

artículo científico publicado en 2022

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

artículo científico publicado en 2015

Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'

artículo científico publicado en 2020

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

artículo científico publicado en 2013

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

artículo científico publicado en 2013

Predictors of disability worsening in clinically isolated syndrome.

artículo científico publicado en 2015

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

artículo científico publicado en 2004

Risk of relapse phenotype recurrence in multiple sclerosis.

artículo científico publicado en 2014

Risk of secondary progressive multiple sclerosis: A longitudinal study

scientific article published on 09 August 2019

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

artículo científico publicado en 2014

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

artículo científico publicado en 2013

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis

scientific article published on 20 September 2018

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

artículo científico publicado en 2015

The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform

artículo científico publicado en 2013

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease

artículo científico publicado en 2014

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

artículo científico publicado en 2015

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

artículo científico publicado en 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

artículo científico publicado en 2017

Lista de obras de Michael Barnett

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Comparative efficacy of switching to natalizumab in active multiple sclerosis

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Defining reliable disability outcomes in multiple sclerosis.

Defining secondary progressive multiple sclerosis

Diffusivity in multiple sclerosis lesions: At the cutting edge?

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes)

Incidence and prevalence of NMOSD in Australia and New Zealand.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.

Molecular pathogenesis of neuromyelitis optica

Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Predictors of disability worsening in clinically isolated syndrome.

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

Risk of relapse phenotype recurrence in multiple sclerosis.

Risk of secondary progressive multiple sclerosis: A longitudinal study

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.